Receptor/gene/protein-mediated Signaling Connects Methylprednisolone Exposure to Metabolic and Immune-related Pharmacodynamic Actions in Liver

Overview

Journal J Pharmacokinet Pharmacodyn

Publisher Springer

Specialty Pharmacology

Date 2018 Apr 29

PMID 29704219

Citations 6

Authors

Vivaswath S Ayyar

Siddharth Sukumaran

Debra C DuBois

Richard R Almon

Jun Qu

William J Jusko

Affiliations

Soon will be listed here.

Abstract

A multiscale pharmacodynamic model was developed to characterize the receptor-mediated, transcriptomic, and proteomic determinants of corticosteroid (CS) effects on clinically relevant hepatic processes following a single dose of methylprednisolone (MPL) given to adrenalectomized (ADX) rats. The enhancement of tyrosine aminotransferase (TAT) mRNA, protein, and enzyme activity were simultaneously described. Mechanisms related to the effects of MPL on glucose homeostasis, including the regulation of CCAAT-enhancer binding protein-beta (C/EBPβ) and phosphoenolpyruvate carboxykinase (PEPCK) as well as insulin dynamics were evaluated. The MPL-induced suppression of circulating lymphocytes was modeled by coupling its effect on cell trafficking with pharmacogenomic effects on cell apoptosis via the hepatic (STAT3-regulated) acute phase response. Transcriptomic and proteomic time-course profiles measured in steroid-treated rat liver were utilized to model the dynamics of mechanistically relevant gene products, which were linked to associated systemic end-points. While time-courses of TAT mRNA, protein, and activity were well described by transcription-mediated changes, additional post-transcriptional processes were included to explain the lack of correlation between PEPCK mRNA and protein. The immune response model quantitatively discerned the relative roles of cell trafficking versus gene-mediated lymphocyte apoptosis by MPL. This systems pharmacodynamic model provides insights into the contributions of selected molecular events occurring in liver and explores mechanistic hypotheses for the multi-factorial control of clinically relevant pharmacodynamic outcomes.

Citing Articles

High-quality and robust protein quantification in large clinical/pharmaceutical cohorts with IonStar proteomics investigation.

Shen S, Wang X, Zhu X, Rasam S, Ma M, Huo S Nat Protoc. 2022; 18(3):700-731.

PMID: 36494494 PMC: 10673696. DOI: 10.1038/s41596-022-00780-w.

Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Ayyar V, Jusko W Pharmacol Rev. 2020; 72(2):414-438.

PMID: 32123034 PMC: 7058984. DOI: 10.1124/pr.119.018101.

Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part III: Estrous Cycle and Estrogen Receptor-Dependent Antagonism of Glucocorticoid-Induced Leucine Zipper (GILZ) Enhancement by Corticosteroids.

Ayyar V, DuBois D, Almon R, Jusko W J Pharmacol Exp Ther. 2019; 370(2):337-349.

PMID: 31197018 PMC: 6658921. DOI: 10.1124/jpet.119.257543.

Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems.

Ahmed S, Ellis M, Li H, Pallucchini L, Stein A J Pharmacokinet Pharmacodyn. 2019; 46(3):287-304.

PMID: 31037615 DOI: 10.1007/s10928-019-09638-3.

Modeling Corticosteroid Pharmacogenomics and Proteomics in Rat Liver.

Ayyar V, Sukumaran S, DuBois D, Almon R, Jusko W J Pharmacol Exp Ther. 2018; 367(1):168-183.

PMID: 30087156 PMC: 6146373. DOI: 10.1124/jpet.118.251959.

References

Sun Y, Jusko W . Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci. 1998; 87(6):732-7. DOI: 10.1021/js970414z. View

Stark J, Werner S, Homrighausen S, Tang Y, Krieg M, Derendorf H . Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide. J Pharmacokinet Pharmacodyn. 2006; 33(4):441-59. DOI: 10.1007/s10928-006-9013-5. View

Kamisoglu K, Acevedo A, Almon R, Coyle S, Corbett S, DuBois D . Understanding Physiology in the Continuum: Integration of Information from Multiple - Levels. Front Pharmacol. 2017; 8:91. PMC: 5327699. DOI: 10.3389/fphar.2017.00091. View

Sukumaran S, Jusko W, DuBois D, Almon R . Mechanistic modeling of the effects of glucocorticoids and circadian rhythms on adipokine expression. J Pharmacol Exp Ther. 2011; 337(3):734-46. PMC: 3101012. DOI: 10.1124/jpet.111.179960. View

Kamisoglu K, Sukumaran S, Nouri-Nigjeh E, Tu C, Li J, Shen X . Tandem analysis of transcriptome and proteome changes after a single dose of corticosteroid: a systems approach to liver function in pharmacogenomics. OMICS. 2015; 19(2):80-91. PMC: 4322790. DOI: 10.1089/omi.2014.0130. View

Ramakrishnan R, DuBois D, Almon R, Pyszczynski N, Jusko W . Pharmacodynamics and pharmacogenomics of methylprednisolone during 7-day infusions in rats. J Pharmacol Exp Ther. 2001; 300(1):245-56. DOI: 10.1124/jpet.300.1.245. View

Yao Z, Hoffman E, Ghimbovschi S, DuBois D, Almon R, Jusko W . Mathematical modeling of corticosteroid pharmacogenomics in rat muscle following acute and chronic methylprednisolone dosing. Mol Pharm. 2008; 5(2):328-39. PMC: 4196382. DOI: 10.1021/mp700094s. View

Sun Y, Dubois D, Almon R, Jusko W . Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokinet Biopharm. 1999; 26(3):289-317. DOI: 10.1023/a:1023233409550. View

Ayyar V, Almon R, DuBois D, Sukumaran S, Qu J, Jusko W . Functional proteomic analysis of corticosteroid pharmacodynamics in rat liver: Relationship to hepatic stress, signaling, energy regulation, and drug metabolism. J Proteomics. 2017; 160:84-105. PMC: 5455150. DOI: 10.1016/j.jprot.2017.03.007. View

10.

Pilkis S, GRANNER D . Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol. 1992; 54:885-909. DOI: 10.1146/annurev.ph.54.030192.004321. View

11.

Mager D, Lin S, Blum R, Lates C, Jusko W . Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol. 2003; 43(11):1216-27. DOI: 10.1177/0091270003258651. View

12.

Ruiz-Irastorza G, Danza A, Khamashta M . Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012; 51(7):1145-53. DOI: 10.1093/rheumatology/ker410. View

13.

Kmiec Z . Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol. 2001; 161:III-XIII, 1-151. DOI: 10.1007/978-3-642-56553-3. View

14.

Ramakrishnan R, DuBois D, Almon R, Pyszczynski N, Jusko W . Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J Pharmacokinet Pharmacodyn. 2002; 29(1):1-24. PMC: 4207287. DOI: 10.1023/a:1015765201129. View

15.

Wald J, Jusko W . Prednisolone pharmacodynamics: leukocyte trafficking in the rat. Life Sci. 1994; 55(19):PL371-8. DOI: 10.1016/0024-3205(94)00693-8. View

16.

Jin J, DuBois D, Almon R, Jusko W . Receptor/gene-mediated pharmacodynamic effects of methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver. J Pharmacol Exp Ther. 2004; 309(1):328-39. DOI: 10.1124/jpet.103.061515. View

17.

Hazra A, DuBois D, Almon R, Snyder G, Jusko W . Pharmacodynamic modeling of acute and chronic effects of methylprednisolone on hepatic urea cycle genes in rats. Gene Regul Syst Bio. 2009; 2:1-19. PMC: 2733100. View

18.

Baumann H, Prowse K, Marinkovic S, Won K, Jahreis G . Stimulation of hepatic acute phase response by cytokines and glucocorticoids. Ann N Y Acad Sci. 1989; 557:280-95, discussion 295-6. DOI: 10.1111/j.1749-6632.1989.tb24021.x. View

19.

Jurado L, Song S, Roesler W, Park E . Conserved amino acids within CCAAT enhancer-binding proteins (C/EBP(alpha) and beta) regulate phosphoenolpyruvate carboxykinase (PEPCK) gene expression. J Biol Chem. 2002; 277(31):27606-12. DOI: 10.1074/jbc.M201429200. View

20.

Salinas M, Wallace R, Grisolia S . Comparative studies in vivo and in vitro of rat-liver enzymes. Eur J Biochem. 1974; 44(2):375-81. DOI: 10.1111/j.1432-1033.1974.tb03494.x. View